MK-6482 appeared well-tolerated and showed promising single-agent activity among heavily pretreated patients with clear cell renal cell carcinoma, according to results of a first-in-human phase 1/phase 2 study presented at Genitourinary Cancers Symposium.

“A new drug as a single agent showing an overall response rate of 24% across all risk categories — poor, intermediate and good — and in a heavily refractory population is quite promising,” Tony K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology and of the Kidney Cancer Center at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg professor of medicine at Harvard Medical School, said in a press release.